QD

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

Retrieved on: 
Monday, March 11, 2024

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, will provide clinical and pipeline updates today during its virtual investor event.

Key Points: 
  • We believe these data support the potential for VTX3232 to emerge as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory diseases.
  • We believe these data establish compelling clinical proof of concept for our peripheral NLRP3 inhibitor VTX2735.
  • At our virtual investor event, we will present data from the ongoing Phase 2 open-label extension.
  • Ventyx will host a virtual investor event today, Monday, March 11, 2024 from 11:00AM to 12:30PM ET.

Cyber Acoustics Revolutionizes the Training of Call Center Agents

Retrieved on: 
Tuesday, March 5, 2024

In addition, the HS-1500BT allows coaches the freedom to move about the call center floor while maintaining a simultaneous secure wireless connection to their computer or tablet.

Key Points: 
  • In addition, the HS-1500BT allows coaches the freedom to move about the call center floor while maintaining a simultaneous secure wireless connection to their computer or tablet.
  • In addition, one HS-1500BT wireless headset can be shared with any number of agents, making it a cost-effective solution for contact centers.
  • This process can be repeated with any number of agent’s AC-204TR headsets that have been pre-paired to the coach’s HS-1500BT.
  • “The AC-204TR offers a way for BPOs to improve agent training by making it easier for coaches to connect to agent’s calls and offer guidance directly.

Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

Retrieved on: 
Friday, March 1, 2024

VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of atopic dermatitis (AD).

Key Points: 
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of atopic dermatitis (AD).
  • VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. and is the same strength and formulation being studied in the ADORING Phase 3 development program for AD.
  • The following posters will be viewable onsite at the San Diego Convention Center.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Retrieved on: 
Tuesday, January 30, 2024

Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies.

Key Points: 
  • Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies.
  • The overall response rate (ORR) among R/R patients treated with ziftomenib and ven/aza was 53% (8/15).
  • As of the data cutoff, 80% (16/20) of patients remain on trial, including 100% (11/11) of all NPM1-m patients.
  • “We are highly encouraged by these preliminary combination data for ziftomenib and believe they support advancement into the frontline AML population,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

Retrieved on: 
Monday, January 29, 2024

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers.
  • “We have made significant progress in our commitment to advancing new solutions for RAS pathway-driven cancers and look forward to an exciting and catalyst-filled year ahead.
  • Safety and tolerability continued to be favorable and consistent with previously reported data.
  • Entered into a discovery and development collaboration with GenFleet Therapeutics (“GenFleet”) to advance three oncology discovery programs targeting RAS pathway-driven cancers.

Scrona and Avantama Collaborate to Redefine Quantum Dot Processing with EHD High Patterning Resolution for Displays

Retrieved on: 
Tuesday, January 23, 2024

ZURICH, Jan. 23, 2024 /PRNewswire/ -- Scrona AG, the additive manufacturing startup and world record holder of the smallest ever printed color picture, and Avantama, a leader in high-tech materials for electronics, today announced that they have successfully processed high-performance quantum dot (QD) ink using Scrona's electrohydrodynamic (EHD) inkjet printing. This collaboration combines the benefits of the inkjet process with high-patterning resolution to drive a new generation of efficient and cost effective MicroLED displays, while also increasing color purity and brightness, and improving overall pixel production tact time. 

Key Points: 
  • "We continue to find new applications of EHD that will meet the demands of the industry by offering an additive, completely waste-free process with higher resolution capabilities than lithography patterning," said Dr. Patrick Galliker, co-founder and CEO of Scrona.
  • "Conventional inkjet printing is not a viable option for emerging MicroLED displays because they use much smaller pixels than QD-OLED displays," said Dr. Norman Lüchinger, co-founder and CTO at Avantama.
  • Scrona print head technology processes QD inks using EHD inkjet printing, whereby droplets are ejected from a nozzle by electrostatic forces.
  • Perovskite QDs have the highest weight-based absorption compared to others QDs, and this directly translates to very high OD/thickness values.

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Retrieved on: 
Wednesday, January 10, 2024

WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its Phase 2b study of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis (AD) (ATI-1777-AD-202; NCT05432596). ATI-1777 was generated from Aclaris’ proprietary KINect® drug discovery platform.

Key Points: 
  • For this trial, ATI-1777 was developed as an emollient-containing spray formulation.
  • The trial randomized 250 patients with mild, moderate or severe AD, including adults and children as young as 12 years old, across 30 clinical trial sites in the United States.
  • “The trial demonstrated efficacy results, a pharmacokinetic profile and safety results that were consistent with what was seen in the Phase 2a trial of ATI-1777,” stated Dr. Neal Walker, Aclaris’ Chairman of the Board of Directors.
  • These results are particularly encouraging given the higher than anticipated vehicle response and the mid-study inclusion of a milder patient population.

Alienware Doubles QD-OLED Family with Two World's First Gaming Monitors

Retrieved on: 
Monday, January 8, 2024

ROUND ROCK, Texas, Jan. 8, 2024 /PRNewswire/ -- Today at CES 2024, Alienware is building on our legacy of display innovation with two new world's-first QD-OLED gaming monitors1.

Key Points: 
  • ROUND ROCK, Texas, Jan. 8, 2024 /PRNewswire/ -- Today at CES 2024, Alienware is building on our legacy of display innovation with two new world's-first QD-OLED gaming monitors1.
  • Introducing the Alienware 32 4K QD-OLED Gaming Monitor (AW3225QF) and Alienware 27 360Hz QD-OLED Gaming Monitor (AW2725DF) - two new, advanced gaming displays that expand our celebrated, award-winning QD-OLED family which first debuted at CES 2022.
  • Introducing the AW3225QF, a 2024 CES Innovation Award Honoree, which marries beauty and performance for the ultimate visual experience.
  • Alienware monitors' 3-layer structure of Quantum Dots allows blue self-emitting pixels and a layer of QD nanoparticles on top to create the other colors you see on the screen.

TCL Unveils Dramatically Enhanced Home Theater Lineup at CES 2024, Including New Premium QD Mini LED and an All New 115" TV

Retrieved on: 
Monday, January 8, 2024

LAS VEGAS, Jan. 8, 2024 /PRNewswire/ -- TCL®, one of the world's best-selling and leading technology companies, today announced new TVs and sound bars for unprecedented home entertainment solutions at the 2024 International Consumer Electronics Show (CES). Inspiring greatness in homes nationwide with its innovation, TCL continues to break down the barriers in home theater with its award-winning family of products. Its most premium line of QLED TVs aims to deliver better performance and bigger screens, featuring a broader range of Mini LED models and further enhancements for unmatched gaming, cinema, and sports experiences with complimentary sound bar offerings.

Key Points: 
  • TCL will raise the bar in 2024 with an expanded and enhanced TV line-up.
  • TCL will continue to segment the TV line into S Class for Smart TV, and Q Class for QLED TV, introducing new premium QD Mini LED inside Q Class.
  • The S5 incorporates a High Brightness LED Backlight for up to 25% more brightness and enhanced color, resulting in more vibrant images.
  • "In 2024, TCL will raise the bar with our new premium QD Mini LED, providing a never before seen level of TV picture quality.

Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

Retrieved on: 
Saturday, December 9, 2023

At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%.

Key Points: 
  • At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%.
  • As presented at the conference, we have shown for the first time the long-term follow-up data of our 100 mg patient cohorts.
  • By increasing the dose from 100 mg to 200 mg, we are excited about nearly doubling the percentage of patients treated with BMF-219 having a robust HbA1c reduction of 1% or more, 22 weeks after the last dose.
  • Phase II consists of multiple ascending dose (MAD) cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.